InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.
The new study from Turku Bioscience provides new insights into how genetic variation associated with immune mediated diseases can influence T-cell function and regulation of immune response. The study was published in Nucleic Acid Research.
A recent international study showed that higher pollen concentrations in the air correlate with increased COVID-19 infection rates. Pollen exposure weakens the response of immune system to some seasonal respiratory viruses. The effect was not connected with pollen allergy.
The research groups of Academy Professor Riitta Lahesmaa and Research Director Laura Elo from Turku Centre for Biotechnology have discovered new proteins that regulate T cells in the human immune system. Some of these proteins can provide possible new targets for drug development in treating immune-mediated diseases.